Conditas, SYN|thesis med chem ink drug discovery deal
Conditas will represent the Melbourne and Shanghai based company as its agent for business development and sales of services in the US. The Conditas Group Jr. founder and
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.